VistaGen Therapeutics (VTGN) Stock Forecast and Price Target (2026)
Last updated July 2026
Short answer
There is no meaningful analyst consensus for VistaGen Therapeutics (VTGN): too few analysts publish estimates on it for an average target to mean anything. That is normal for smaller and newer companies and says nothing about the business. What is left is the setup, the drivers and the risks below, which you assess yourself rather than starting from someone else's model. Walnut is not an investment adviser.
Why VTGN has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with VTGN. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.
Figures are approximate and tied to the asOf date; verify live numbers before acting. Traditional valuation ratios like P/E do not apply to a pre-revenue, loss-making biotech. What matters is the probability-weighted value of the pipeline, the odds and timing of upcoming trial readouts, and whether cash lasts until those catalysts. A very low share price and small market cap also raise the practical risk of a reverse split or delisting, which are separate from the science.
What could move VTGN from here
In short: the drivers cited most often are Fasedienol Phase 3 outcomes, Novel pherine mechanism, Broader CNS pipeline optionality. The risk cited most often against it is the overriding risk is clinical and binary: VistaGen has no approved products, and multiple Phase 3 fasedienol trials have missed their primary endpoints, so the entire thesis could collapse on a single disappointing readout or a negative regulatory response.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the VTGN is it a buy page. This page deliberately stops at the numbers.
Investing in VistaGen Therapeutics with AI
Connect the broker you already use and ask Walnut's AI how VTGN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the price target for VistaGen Therapeutics (VTGN)?
+
There is no meaningful consensus price target for VTGN, because too few analysts publish on it. That is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does VTGN have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean you are doing the analysis yourself rather than starting from someone else's model.
What could move VTGN?
+
The drivers and the risks are laid out on this page and in more depth on the VTGN "is it a buy" page. Without analyst estimates to anchor to, the honest framing is scenarios rather than a number.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a July 2026 data pull of published third-party research, are approximate, and change constantly. Verify current figures with your broker before acting on them.